在真菌角膜炎中PPAR的作用
Hongyan Zhou1, Hong Zhang1, Miaomiao Bi1
1Department of Ophthalmology, The China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Frontiers in immunology
|January 7, 2025
概括
由于检测迟到和药物无效,治疗真菌角膜炎 (FK) 很困难. 过氧体增殖器激活受体 (PPAR) 在减少炎症和氧化应激方面表现有前途,为FK提供了新的治疗途径.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 由于诊断延迟和抗真菌功效有限,真菌角膜炎 (FK) 存在治疗挑战.
- 菌感染引发角膜免疫反应,氧化应激和通过炎症介质的组织损伤.
- 过氧体增殖器激活受体 (PPAR) 是参与抗氧化,抗炎和免疫调节的核受体.
研究的目的:
- 探索Peroxisome增殖器激活受体 (PPARs) 在治疗真菌角膜炎 (FK) 中的潜在治疗作用.
- 调查PPARs,特别是PPARγ如何减轻FK中的免疫-炎症和氧化应激损伤.
主要方法:
- 关于真菌角膜炎病原和免疫反应的现有文献的综述.
- 对PPAR亚型 (PPARα,PPARβ/δ,PPARγ) 在眼组织和炎症过程中的已知功能的分析.
- 探索PPAR介导的机制,包括巨细胞极化和活性氧物种 (ROS) 调节.
主要成果:
- PPARs在抗氧化反应,炎症控制和免疫调节中发挥着重要作用.
- PPARγ激活可以促进有益的巨细胞两极分化,并通过控制ROS生产来减少氧化应激.
- 以前的研究表明,PPARα激动剂在糖尿病角膜病变,角膜神经病变和血管生成等疾病中具有治疗潜力.
结论:
- PPARs是治疗真菌角膜炎的一个有希望的治疗点.
- 调节PPAR活性可以提供一种新的策略,以对抗FK特有的免疫-炎症和氧化损伤.
- 对PPAR激动剂的进一步研究可能会改善真菌角膜炎的治疗结果.
相关概念视频
01:28Fungal Phylum Microsporidia
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...